Biphosphonate-associated osteonecrosis of the maxillary bones;Ostéonécrose des maxillaires liée aux bisphosphonates

Revue Medicale Suisse

Volumn 2, Issue 86, 2006, Pages 2575-2576

  Madrid, Carlos ^a  

^a POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; NITROGEN; PAMIDRONIC ACID;

ATTITUDE TO HEALTH; BONE CANCER; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; DEBRIDEMENT; DISEASE SEVERITY; DRUG UTILIZATION; HEALTH PRACTITIONER; HUMAN; INCIDENCE; MAXILLOFACIAL DISORDER; MEDICAL LITERATURE; MEDICAL SPECIALIST; MYELOMA; PRESCRIPTION; PROPHYLAXIS; RISK FACTOR; SEPSIS; SHORT SURVEY;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; MAXILLARY DISEASES; OSTEONECROSIS;

EID: 33751578715     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Gremaud M, Delouche D, Monnerat C. Traitement des métastases osseuses par les bisphosphonates. Rev Med Suisse 2006:2:1861-6.
2. Junod AF, Carrel JP, Richter M, Vogt-Ferrier N. Osteonecrosis of the jaws and bisphosphonates. Rev Med Suisse 2005;1:2537-40.
3. Marx RE. Pamidronate and zoledronate induced avasculkar necrosis of the jaws: A growing epidemic. J Oral Maxillofacial Surg 2003;61:1115-7.
4. Marx RE. Bisphosphonate induced exposed bone (osteonecrosis osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofacial Surg 2005;63:1167-75.
5. Markiewicz MR Margarone JE, Campbell JH, Aguirre A. Bisphosphonate associated osteonecrosis of the jaws: A review of current knowledge. J Am Dental Ass 2005;136:1669-74.
6. Bagan JY, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006;42:327-9.
7. Sarathy AP, Bourgeois SL Jr, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: Two case reports. J Endod 2005; 31:759-63.
8. Scully C, Madrid C, Bagan JV. Dental endosseous implants in the patients on bisphophonate therapy. J Implant Dentistry 2006; 15, sous presse.
9. e Congrès de la Société française de stomatologie et de chirurgie maxillo-faciale. Besançon, 11-13 octobre 2006.
10. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphophonates. N Engl J Med 2005;353:99-102.
11. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23:8580-7.
12. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 2006; Epub sous presse.
13. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Australia 2005;182:417-8.
14. Studer G, Gratz KW, Glanzmann C. Osteoradionecrosis of the mandibula in patients treated with different fractionations. Strahlenther Onkologie 2004;180: 233-40.
15. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated ostéonécroses. J Am Dental Assoc 2005;136:1658-68.
16. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 2006;137:1144-50.
17. Hellstein JW, Marek CL. Bisphosphonate induced osteochemonecrosis of the jaws: An ounce of prevention may be worth a pound of cure. Spec Care Dentist 2006;26:8-12.